Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis

Am J Med. 2020 Aug;133(8):892-894. doi: 10.1016/j.amjmed.2020.02.036. Epub 2020 Apr 5.

Authors

Paul J Hauptman¹, Jonathan S Wall², Mathew S Maurer³

Affiliations

¹ University of Tennessee Graduate School of Medicine, Knoxville Tenn. Electronic address: phauptman@utmck.edu.
² University of Tennessee Graduate School of Medicine, Knoxville Tenn.
³ Columbia University Irving Medical Center, New York NY.

PMID: 32268147
DOI: 10.1016/j.amjmed.2020.02.036

No abstract available

Publication types

Editorial

MeSH terms

Amyloid Neuropathies, Familial / diagnosis*
Amyloid Neuropathies, Familial / drug therapy
Amyloid Neuropathies, Familial / ethnology
Black People
Cardiomyopathies / diagnosis*
Cardiomyopathies / drug therapy
Cardiomyopathies / ethnology
Caribbean Region
Drug Costs
Genetic Predisposition to Disease
Health Services Accessibility*
Healthcare Disparities*
Humans
Mass Screening
Precision Medicine*

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related